Lupus & antiphospholipid syndrome
Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden
Authors' conclusion
The prevalence of coexisting psoriasis in patients with SLE in Sweden was estimated to be 3.4-4.9%. Individuals with comorbid psoriasis reported more pain and were more likely to be prescribed methotrexate than those without psoriasis.
Study context
- Population
- Patients with SLE (1982 ACR and/or 2012 SLICC criteria) from Linköping University Hospital, and subjects with SLE living in Sweden in 2022 from the National Patient Register (NPR)351 regional
- Exposure
- SLE with vs without comorbid psoriasis
- Outcome
- Prevalence of psoriasis in SLE
Methodological detailsregional cohort (tertiary referral centre), nationwide register cohort (National Patient Register)
- Regional cohort (tertiary referral centre)
- Nationwide register cohort (National Patient Register)
Main finding
As reported in the abstract
Prevalence of coexisting psoriasis in SLE
Observational data: associations, not effects.
Further findings
| Outcome | SLE with psoriasis | P value |
|---|---|---|
| Pain (VAS)With psoriasis vs Without coexisting psoriasis | median 45.5 (IQR 23.3–58.3) /100 mm | P < 0.04 |
- Pain (VAS): Without coexisting psoriasis median 27.0 (IQR 7.0–50.5) /100 mm
Sex
- Men proportionally more common with comorbid psoriasis in both cohorts
Damage accrual and clinical phenotypes
- No differences between the two groups
MTX prescription (nationwide cohort)
- More frequently prescribed MTX with psoriasis
Original publication
Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden. Lupus Sci Med. Published 4 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →